

AUSPICES

Azienda Ospedaliero Universitaria delle Marche

AIL - Associazione Italiana contro Leucemie-Linfomi e Mieloma

Università Politecnica delle Marche

MEETING VENUE

Ego Hotel

Via Flaminia, 220 - 60126 Ancona

Tel.: +39 071 2181262

ITALIAN CME CREDITS

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828-415098
- No. 4 CME credits for Physicians (disciplines: hematology, respiratory diseases, infectious diseases, interna medicine, oncology, paediatrics, pathological anatomy, clinical pathology), Biologist, Nurse, Paediatric nurse and Medical technician biomedical laboratory
- Educational objective: "guidelines-protocols-procedures"

OFFICIAL LANGUAGE

English

REGISTRATION

Registration is free and available at www.ercongressi.it - section "I nostri congressi/anno 2024" until October 14, 2024.

SCIENTIFIC SECRETARIAT

Prof. Attilio Olivieri

Clinica di Ematologia

Università Politecnica delle Marche

Azienda Ospedaliero Universitaria delle Marche

ORGANIZING SECRETARIAT

Studio ER Congressi Srl

Via de' Poeti, 1/7 - 40124 Bologna

Tel.: +39 051 4210559

E-mail: ercongressi@ercongressi.it

www.ercongressi.it

With an unrestricted educational grant of



SOLVE
ON.

neovii

sanofi



program

GITMO Symposium

HOT TOPICS IN CHRONIC GVHD



OCTOBER 20-21, 2024

ANCONA, Ego Hotel

Sunday **October 20, 2024**

14:30 Open registration & welcome coffee

15:00-15:20 Welcome & introduction
A. Olivieri (Ancona)

15:20-18:00 **cGVHD part I**
Chairmen: F. Ciceri (Milano), M. Martino (Reggio Calabria)

15:20 cGVHD prophylaxis: are new strategies better than conventional tools? Yes
A. Nagler (Tel Aviv, IL)

15:40 cGVHD prophylaxis: are new strategies better than conventional tools? No
F. Bonifazi (Bologna)

16:00 ECP in the era of new drugs for cGVHD: which role and which schedule?
H. Greinix (Graz, AT)

16:20 Non immune effector targets in cGVHD
A. Olivieri (Ancona)

16:40 Ruxolitinib-refractory GVHD: it is still a worth definition?
M. Mohty (Paris, FR)

17:00 What to do in ruxolitinib-refractory cGVHD?
D. Wolff (Regensburg, DE)

17:20 Overlap cGVHD: assessment in the real life and proposal of a prospective GITMO study
D. Pulanic (Zagreb, HR), J. Mariotti (Milano)

17:40 Discussion

18:00 Closing part I

Monday **October 21, 2024**

08:45-09:45 **cGVHD part II: burning topics in lung cGVHD**
Chairmen: A. Bacigalupo (Genova), G. Moroncini (Ancona)

08:45 Round table: common and atypical lung manifestations in cGVHD in idiopathic pulmonary fibrosis and in CLAD
D. Wolff (Regensburg, DE), M. Bonifazi (Ancona), F. Meloni (Padova)

09:45 Closing part II, remarks and farewell coffee

